Comment on

• Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.

  Hulot JS, Chevalier B, Belle L, Cayla G, Khalife K, Funck F, Berthier R, Piot C, Tafflet M, Montalescot G; GIANT Investigators. Hulot JS, et al. JACC Cardiovasc Interv. 2020 Mar 9;13(5):621-630. doi: 10.1016/j.jcin.2020.01.219. JACC Cardiovasc Interv. 2020. PMID: 32139220
• Subclassification of CYP2C19 Genotyping for Better-Adjusted Thienopyridine Treatment.

  Cha JJ, Lim DS. Cha JJ, et al. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1495. doi: 10.1016/j.jcin.2020.04.010. JACC Cardiovasc Interv. 2020. PMID: 32553339 No abstract available.